Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease
Autore:
Nieto, Y; Cagnoni, PJ; Shpall, EJ; Matthes, S; Baron, A; Jones, RB; Bearman, SI;
Indirizzi:
Univ Colorado, Hlth Sci Ctr, Bone Marrow Transplant Program, Denver, CO 80262 USA Univ Colorado Denver CO USA 80262 ransplant Program, Denver, CO 80262 USA Univ Colorado, Dept Biostat, Denver, CO 80262 USA Univ Colorado Denver COUSA 80262 ado, Dept Biostat, Denver, CO 80262 USA
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 7, volume: 5, anno: 1999,
pagine: 1731 - 1737
SICI:
1078-0432(199907)5:7<1731:PITOHC>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW SUPPORT; COLONY-STIMULATING FACTOR; BLOOD PROGENITOR CELLS; LONG-TERM SURVIVAL; COMBINATION CHEMOTHERAPY; LOCOREGIONAL RECURRENCE; MULTIMODALITY THERAPY; PROGNOSTIC FACTORS; ADJUVANT TREATMENT; RANDOMIZED TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Nieto, Y Univ Colorado, Hlth Sci Ctr, Bone Marrow Transplant Program, 4200E 9th Ave,B-190, Denver, CO 80262 USA Univ Colorado 4200 E 9th Ave,B-190 Denver CO USA 80262 80262 USA
Citazione:
Y. Nieto et al., "Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease", CLIN CANC R, 5(7), 1999, pp. 1731-1737

Abstract

The purpose of this study was to assess the efficacy of high-dose chemotherapy (HDC) with autologous stem cell transplant in stage IV breast cancer patients with minimal metastases. Eligible patients had (a) disease that could be resected en bloc and/or irradiated with curative intent using a single field and could, thus, be rendered as having no evidence of disease (NED); and/or (b) <5% bone marrow involvement. From September 1991 to August 1997, 40 consecutive patients were prospectively entered on the study, Pre-HDClocal treatment consisted of surgery (n = 31) and radiotherapy (XRT; n = 3), All patients received HDC with cyclophosphamide, cisplatin, and 1,3-bis(2-chloroethyl)-1-nitrosourea and autologous stem cell transplant, with or without CD34 selection. Following HDC, 22 patients received XRT. Four patients died of treatment-related complications. Eighteen patients developed grade 3 nonhematological toxicities (15 lung, 2 cardiomyopathy, and 1 optic neuritis), which resolved with therapy, Within a median follow-up of 49 (15-91) months, 14 patients had relapsed, Twenty-five patients (62.5%) were alive, and 22 patients (55%) were alive and free of disease. Median event-free and overall survivals were 43 and 77 months, respectively, In the subset ofpatients with one metastatic site, 17 of 24 (68%) remained relapse free. Grade 2 tumors, a single metastatic site, and delivery of XRT were favorablepredictors of relapse-free survival in univariate but not multivariate analyses. Inclusion of HDC, as described, in the multimodal treatment of stageIV breast cancer patients with minimal metastases is promising. These results warrant prospective randomized trials with a HDC-containing arm in thispatient population.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 19:49:30